Literature DB >> 17913795

Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.

Zhiming Wen1, Todd E Dumas, Sarah J Schrieber, Roy L Hawke, Michael W Fried, Philip C Smith.   

Abstract

Silymarin, a mixture of polyphenolic flavonoids extracted from milk thistle (Silybum marianum), is composed mainly of silychristin, silydianin, silybin A, silybin B (SB(B)), isosilybin A (ISB(A)), and isosilybin B. In this study, the plasma concentrations of free (unconjugated), conjugated (sulfated and glucuronidated), and total (free and conjugated) silymarin flavonolignans were measured using liquid chromatography-electrospray ionization-mass spectrometry, after a single oral dose of 600 mg of standardized milk thistle extracts to three healthy volunteers. Pharmacokinetic analysis indicated that silymarin flavonolignans were rapidly eliminated with short half-lives (1-3 and 3-8 h for free and conjugated, respectively). The AUC(0-->infinity) values of the conjugated silymarin flavonolignans were 4- to 30-fold higher than those of their free fractions, with SB(B) (mean AUC(0-->infinity) = 51 and 597 microg x h/l for free and conjugated, respectively) and ISB(A) (mean AUC(0-->infinity) = 30 and 734 microg x h/l for free and conjugated, respectively) exhibiting higher AUC(0-->infinity) values in comparison with other flavonolignans. Near the plasma peak times (1-3 h), the free, sulfated, and glucuronidated flavonolignans represented approximately 17, 28, and 55% of the total silymarin, respectively. In addition, the individual silymarin flavonolignans exhibited quite different plasma profiles for both the free and conjugated fractions. These data suggest that, after oral administration, silymarin flavonolignans are quickly metabolized to their conjugates, primarily forming glucuronides, and the conjugates are primary components present in human plasma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913795     DOI: 10.1124/dmd.107.017566

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  55 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

3.  In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin.

Authors:  Ebru Evren; Erkan Yurtcu
Journal:  Folia Microbiol (Praha)       Date:  2015-05-04       Impact factor: 2.099

4.  A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model.

Authors:  Michelle L Montonye; Dan-Dan Tian; Tarana Arman; Katherine D Lynch; Bruno Hagenbuch; Mary F Paine; John D Clarke
Journal:  J Pharmacol Exp Ther       Date:  2019-08-16       Impact factor: 4.030

5.  Effect of silymarin in the prevention of Cisplatin nephrotoxicity, a clinical trial study.

Authors:  Ali Momeni; Ali Hajigholami; Shohreh Geshnizjani; Soleiman Kheiri
Journal:  J Clin Diagn Res       Date:  2015-04-01

6.  Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.

Authors:  Wen-Yi Li; Guo Yu; Renee M Hogan; Rajesh Mohandas; Reginald F Frye; Eric Gumpricht; John S Markowitz
Journal:  Clin Ther       Date:  2017-12-19       Impact factor: 3.393

7.  Silibinin Inhibits Proliferation and Migration of Human Hepatic Stellate LX-2 Cells.

Authors:  Devaraj Ezhilarasan; Jonathan Evraerts; Sid Brice; Pedro Buc-Calderon; Sivanesan Karthikeyan; Etienne Sokal; Mustapha Najimi
Journal:  J Clin Exp Hepatol       Date:  2016-01-13

8.  Silymarin reduces profibrogenic cytokines and reverses hepatic fibrosis in chronic murine schistosomiasis.

Authors:  Hílton Antônio Mata-Santos; Fabianno Ferreira Dutra; Carolina Carneiro Rocha; Fabiana Gonçalves Lino; Fabiola Ramos Xavier; Leandro Andrade Chinalia; Bryan Hudson Hossy; Morgana Teixeira Lima Castelo-Branco; Anderson Junger Teodoro; Claudia N Paiva; Alexandre dos Santos Pyrrho
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

9.  Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.

Authors:  Scott J Brantley; Nicholas H Oberlies; David J Kroll; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2009-11-24       Impact factor: 4.030

Review 10.  Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.

Authors:  Stephen J Polyak; Peter Ferenci; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2013-03       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.